| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.029 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.032 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |